Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEC with docosahexaenoic acid
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This appears to be a modified version of the standard FEC (Fluorouracil, Epirubicin, Cyclophosphamide) chemotherapy regimen with the addition of docosahexaenoic acid. The standard FEC combination is commonly used in the treatment of breast cancer. In this regimen, fluorouracil acts as a pyrimidine antagonist, epirubicin is an anthracycline that inhibits DNA and RNA synthesis, and cyclophosphamide is an alkylating agent. The addition of docosahexaenoic acid to this combination is not documented in the provided search results, suggesting this may be an experimental or investigational modification of the standard regimen.
- Other names
- CEF with docosahexaenoic acid
02
Targets
FFAR4 (Free fatty acid receptor 4)TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)DNA
Beyond the preview
Go deeper on FEC with docosahexaenoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEC with docosahexaenoic acid.